Background: Type 2 diabetes mellitus (T2DM), a chronic metabolic disorder requiring sustained glycemic control to prevent complications. Traditional in-clinic care often limits patient engagement to periodic visits, leaving gaps in continuous diabetes management. Digital health interventions, including virtual two way patient engagement between patients and the care team may enhance adherence and outcomes. However, the impact of different engagement modalities on glycemic control remains underexplored. This study evaluates the impact of virtual patient engagement within the GluCare hybrid care model on glycemic control in individuals with T2DM. Methods: This retrospective observational study included T2DM patients(n=125) enrolled in GluCare’s hybrid care program. Participants were stratified into two groups based on glycemic control: controlled (HbA1c <7%) and poorly controlled (HbA1c ≥7%). Patient engagement was categorized into inbound (patient-initiated) and outbound (provider-initiated) interactions. Clinical and metabolic parameters, including HbA1c, blood pressure, lipid profile, inflammatory markers, renal function, and anthropometric measures, were assessed at baseline and 12 months. Results: Participants in the poorly controlled group exhibited a mean HbA1c reduction of −2.4% (p < 0.001), while controlled patients improved −0.3% (p < 0.001). This magnitude exceeds the −0.3% to −0.5% typically reported for digital-only interventions, indicating clinically meaningful improvement. The higher number of virtual interactions was associated with improved glycemic control (β = –0.007; 95% CI: –0.011 to –0.002; p = 0.003) and remained significant after adjusting for age, BMI, medication use, and glycemic control group (β = –0.006; 95% CI: –0.010 to –0.002; p = 0.001). Both controlled and poorly controlled groups achieved similar HbA1c levels at 12 months (p = 0.205). Engagement peaked at 3 months and declined thereafter, with outbound interactions consistently exceeding inbound ones However, Poorly controlled group more prescribed on GIP/GLP-1 receptor agonists (59.6%), insulin (75%) and statin therapy (56.8%) compared to the controlled group. Conclusion: Virtual patient engagement, particularly provider-initiated interactions, plays a crucial role in optimizing glycemic control and improving metabolic outcomes in T2DM. Hybrid care models that integrate continuous remote monitoring with periodic in-clinic visits offer a viable approach to sustaining patient adherence.

Bone mineral density (BMD) is a measurement of the amount of minerals, primarily calcium and phosphorus, in bone tissue. Factors that can affect BMD include age, gender, genetics, lifestyle factors, and medical conditions. As people age, the density of their bones starts to decline gradually. Due to hormonal changes during menopause, the chance of developing osteoporosis among women is very high. Genetics also play a role in BMD, with some individuals having a higher genetic predisposition to osteoporosis and lower BMD. Physical activity, alcohol consumption, and smoking are some factors associated with BMD. Regular exercise is a protective factor, whereas other two smoking and excessive alcohol are risk factors. It is important to monitor BMD throughout life to identify any potential health concerns and take steps to prevent bone loss. A healthy lifestyle is an important factor that will help maintain sufficient calcium and vitamin D intake and take medication or supplements as directed by a healthcare professional. Regular physical activity such as walking and running can help promote bone health and maintain BMD.

Introduction: Obesity is a growing global challenge with rising prevalence and incidence rates associated with economic burdens. Despite the presence of a variety of approaches to managing obesity, care remains fragmented, and the transparency of care methodologies used by obesity providers remains limited. Hybrid models of care, which blend both digital tools and in-clinic visits, offer a promising and patient-centered approach. However, the lack of outcome-reporting standards remains a limitation. This study evaluates the effectiveness of Semaglutide and Tirzepatide in managing obesity using the newly developed International Consortium for Health Outcomes Measurement (ICHOM) Obesity standard set. Methods: This study employed a retrospective study design including 528 adults enrolled in a 6-month hybrid care model (meta[bolic], Zone.Health), to manage obesity. Participants were prescribed either a glucagon-like peptide (GLP)-1 receptor agonist (Semaglutide) or dual GLP-1/GIP receptor agonist (Tirzepatide) as part of the program alongside behavioral monitoring and virtual engagement. Outcomes were collected based on the ICHOM Obesity standard set from medical records at baseline, 3 months, and 6 months, and were analyzed using mixed for repeated measures. Subgroup analyses based on dosage bands were done using the Kruskal-Wallis test. Results: Both groups demonstrated significant improvements in weight, body mass index, waist circumference, fat mass, and glycemic control. However, within 6 months, on average, the Tirzepatide group had a greater reduction in weight (13.15 kg), waist circumference (11.34 cm), and HbA1c (0.33%) when compared with the Semaglutide group, with average reductions as 9.54 kg, 7.24 cm, and 0.23%, respectively. In the context of Tirzepatide dosage, all three groups (2.5–5 mg, 5–7.5 mg, and 7.5–15 mg) experienced significant weight loss. Conclusion: This study is among the first to apply the ICHOM Obesity Standard Set to evaluate Semaglutide and Tirzepatide in managing obesity within a hybrid care model. Tirzepatide was associated with superior clinical outcomes when compared with Semaglutide. The integration of standardized outcome reporting enhances transparency and comparability of hybrid interventions. Future studies should explore cost-effectiveness and long-term outcomes to support broader adoption.